Detalhe da pesquisa
1.
A New aDENNDum to Genetics of Childhood Asthma.
Cell
; 164(1-2): 11-13, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26771480
2.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10413): 1648-1659, 2023 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37778358
3.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Am J Hematol
; 95(2): 178-187, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821591
4.
A bispecific antibody strategy to target multiple type 2 cytokines in asthma.
J Allergy Clin Immunol
; 142(4): 1185-1193.e4, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29890236
5.
Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
Expert Opin Ther Pat
; 28(3): 251-276, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29366356
6.
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
MAbs
; 10(1): 34-45, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29035619
7.
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.
Sci Rep
; 6: 31621, 2016 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27546726